Contineum Therapeutics, Inc. (CTNM) Cash Flow Statement
Contineum Therapeutics, Inc. (CTNM) generated -$53.0M of operating cash flow over the twelve months to 2026-06-30, spent $458000 on capital expenditure and had free cash flow of -$53.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTNMContineum Therapeutics, Inc.Follow CTNM — free
—
Price chart with a free account
- Market cap
- 312.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -32.8 | -55.3 | -53.0 | |
| Capital expenditure | 0.5 | 0.2 | -0.5 | |
| Free cash flow | -33.4 | -55.5 | -53.5 | |
| Stock-based compensation | 6.8 | 10.0 | — |
USD millions · SEC XBRL
Contineum Therapeutics, Inc. — questions
- What is Contineum Therapeutics, Inc.'s operating cash flow?
- -$53.0M over the twelve months to 2026-06-30.
- How much does Contineum Therapeutics, Inc. spend on capital expenditure?
- $458000 over the twelve months to 2026-06-30.
- What is Contineum Therapeutics, Inc.'s free cash flow?
- -$53.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Contineum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.